Overview

Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the single-dose bioequivalence of KUDCO's and Wyeth Pharmaceuticals' (Protonix) 40 mg pantoprazole sodium delayed-lease tablets, under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Kremers Urban Development Company
Treatments:
Pantoprazole